Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study.

NCT03449628 is registered in ClinicalTrials.gov with SOFAR S.p.A. as lead sponsor.

NCT NCT03449628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03449628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study.
Lead sponsor
SOFAR S.p.A.
Phase
Not applicable
Overall status
Completed
Start date
November 6, 2017
Completion date
December 30, 2021
Enrollment
264 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

ibs - irritable bowel syndrome